Regenxbio INC. (RGNX) — SEC Filings

Overview

Regenxbio INC. (RGNX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a ARS filed on Apr 14, 2026: REGENXBIO Inc. filed its Annual Report to Security Holders (ARS) on April 14, 2026, for the period ending December 31, 2025. The company, located at 9804 Medical Center Drive, Rockville, MD 20850, operates in the Biological Products sector. The filing details its performance and activities for the f

Sentiment Summary

Across 32 filings, the sentiment breakdown is: 2 bearish, 29 neutral, 1 mixed. The dominant filing sentiment for Regenxbio INC. is neutral.

Filing Type Overview

Regenxbio INC. (RGNX) has filed 1 ARS, 6 10-Q, 11 8-K, 2 DEF 14A, 2 10-K, 10 SC 13G/A with the SEC between Jan 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (32)

• REGENXBIO Files 2025 Annual Report — ARS · Apr 14, 2026 Risk: low
  REGENXBIO Inc. filed its Annual Report to Security Holders (ARS) on April 14, 2026, for the period ending December 31, 2025. The company, located at 9804 Medica
• REGENXBIO Narrows 9-Month Loss Amid Soaring Royalty Revenue — 10-Q · Nov 6, 2025 Risk: high
  REGENXBIO Inc. reported a net loss of $61.941 million for the three months ended September 30, 2025, a slight increase from the $59.597 million net loss in the
• REGENXBIO Inc. Files 8-K: Corporate Updates — 8-K · Aug 18, 2025 Risk: low
  REGENXBIO Inc. filed an 8-K on August 18, 2025, reporting other events and financial statements. The filing details the company's principal executive offices lo
• REGENXBIO's Q2 Loss Widens Amid Rising R&D Costs — 10-Q · Aug 7, 2025 Risk: high
  REGENXBIO Inc. reported a net loss of $70.8 million for the three months ended June 30, 2025, a significant increase from the $57.1 million net loss in the prio
• REGENXBIO Inc. Files 8-K on Shareholder Matters — 8-K · Jun 3, 2025 Risk: low
  REGENXBIO Inc. filed an 8-K on June 3, 2025, reporting on matters submitted to a vote of security holders as of May 30, 2025. The filing details the company's c
• REGENXBIO Inc. Files 8-K: Material Agreement and Financial Update — 8-K · May 19, 2025 Risk: medium
  On May 16, 2025, REGENXBIO Inc. entered into a material definitive agreement, which also created a direct financial obligation for the company. The filing also
• REGENXBIO Files Q1 2025 10-Q — 10-Q · May 12, 2025 Risk: medium
  REGENXBIO Inc. filed its 10-Q for the period ending March 31, 2025. The company's fiscal year ends on December 31st. Key financial data and operational details
• REGENXBIO Inc. Files 2025 Proxy Statement — DEF 14A · Apr 8, 2025 Risk: low
  REGENXBIO Inc. filed a DEF 14A on April 8, 2025, for the fiscal year ending December 31, 2025. The filing details executive compensation and other corporate gov
• REGENXBIO Files 2024 10-K — 10-K · Mar 13, 2025 Risk: medium
  REGENXBIO Inc. filed its 2024 10-K on March 13, 2025, reporting on its fiscal year ending December 31, 2024. The company, a biotechnology firm specializing in b
• REGENXBIO Inc. Files 8-K: Regulation FD Disclosure & Other Events — 8-K · Mar 4, 2025 Risk: low
  On March 3, 2025, REGENXBIO Inc. filed an 8-K report detailing a Regulation FD Disclosure and Other Events. The filing also includes financial statements and ex
• REGENXBIO Inc. Files 8-K: Material Agreement — 8-K · Jan 14, 2025 Risk: medium
  On January 14, 2025, REGENXBIO Inc. entered into a material definitive agreement. The filing also includes Regulation FD disclosures and financial statements/ex
• REGENXBIO Inc. Files 8-K Report — 8-K · Dec 9, 2024 Risk: low
  On December 9, 2024, REGENXBIO Inc. filed an 8-K report. The filing primarily concerns other events and financial statements/exhibits, with no specific material
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• SC 13G/A Filing — SC 13G/A · Nov 12, 2024
• REGENXBIO Q3 Update: $574.8M Cash, R&D Spends Rise — 10-Q · Nov 6, 2024 Risk: medium
  REGENXBIO Inc. filed its 10-Q for the period ending September 30, 2024. The company reported cash, cash equivalents, and marketable securities totaling $574.8 m
• SC 13G/A Filing — SC 13G/A · Nov 4, 2024
• SC 13G/A Filing — SC 13G/A · Oct 17, 2024
• REGENXBIO Inc. Files 8-K: Officer/Director Changes & Compensation — 8-K · Sep 17, 2024 Risk: medium
  REGENXBIO Inc. filed an 8-K on September 17, 2024, reporting events as of September 16, 2024. The filing pertains to the departure of directors or certain offic
• REGENXBIO Appoints New CSO, Dr. Gregory — 8-K · Aug 6, 2024 Risk: medium
  REGENXBIO Inc. announced on August 1, 2024, the appointment of Dr. Philip J. Gregory as Chief Scientific Officer, effective August 5, 2024. Dr. Gregory will rec
• REGENXBIO Inc. Files Q2 2024 10-Q Report — 10-Q · Aug 1, 2024 Risk: medium
  REGENXBIO Inc. filed its 10-Q for the period ending June 30, 2024. The company's fiscal year ends on December 31st. Key financial data and business activities f
• REGENXBIO Appoints New Chief Medical Officer — 8-K · Jun 13, 2024 Risk: low
  On June 12, 2024, REGENXBIO Inc. announced the appointment of Dr. V. Michael Weiss as Chief Medical Officer, effective June 10, 2024. Dr. Weiss will receive an
• REGENXBIO Files 8-K on Shareholder Votes and Financials — 8-K · Jun 3, 2024 Risk: low
  On May 31, 2024, REGENXBIO Inc. filed an 8-K report detailing the submission of matters to a vote of security holders and financial statements. The filing inclu
• REGENXBIO Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 8, 2024 Risk: medium
  REGENXBIO Inc. (RGNX) filed a Quarterly Report (10-Q) with the SEC on May 8, 2024. REGENXBIO Inc. reported its financial results for the quarter ended March 31,
• REGENXBIO Inc. Files Definitive Proxy Statement (DEF 14A) — DEF 14A · Apr 4, 2024 Risk:
  REGENXBIO Inc. (RGNX) filed a Proxy Statement (DEF 14A) with the SEC on April 4, 2024. REGENXBIO Inc. filed a Definitive Proxy Statement (DEF 14A) on April 4, 2
• REGENXBIO Files 8-K: Other Events & Exhibits — 8-K · Mar 11, 2024 Risk: medium
  REGENXBIO Inc. filed an 8-K on March 11, 2024, reporting an event that occurred on March 6, 2024. The filing pertains to 'Other Events' and 'Financial Statement
• REGENXBIO Inc. Files 2023 Annual Report on Form 10-K — 10-K · Feb 27, 2024 Risk: medium
  REGENXBIO Inc. (RGNX) filed a Annual Report (10-K) with the SEC on February 27, 2024. REGENXBIO Inc. filed its 2023 Form 10-K on February 27, 2024. The filing c
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• SC 13G/A Filing — SC 13G/A · Feb 13, 2024
• GIC Cuts REGENXBIO Stake to 8.0% as of Dec 31, 2023 — SC 13G/A · Feb 5, 2024
  GIC Private Ltd, a Singaporean sovereign wealth fund, filed an amended SC 13G/A on February 5, 2024, disclosing its ownership in REGENXBIO Inc. As of December 3
• State Street Amends REGENXBIO Stake, Maintains Passive Position — SC 13G/A · Jan 25, 2024
  State Street Corporation, a major financial institution, filed an amended SC 13G/A on January 25, 2024, indicating its ownership of REGENXBIO Inc. common stock
• JPMorgan Amends REGENXBIO Stake; Ownership Update Filed — SC 13G/A · Jan 25, 2024
  JPMorgan Chase & Co. filed an amended Schedule 13G/A on January 25, 2024, indicating a change in its beneficial ownership of REGENXBIO Inc. common stock as of D
• BlackRock Amends REGENXBIO Stake, Signals Continued Institutional Confidence — SC 13G/A · Jan 19, 2024
  BlackRock Inc. filed an amended SC 13G/A on January 19, 2024, indicating a change in its ownership of REGENXBIO Inc. common stock as of December 31, 2023. This

Related Companies

ABBV · RGX

Frequently Asked Questions